Multi-platform analytical evaluation of the Beckman Coulter Access high-sensitivity troponin I assay across different laboratory sites using Barricor plasma.
Previous analytical evaluations of the Beckman Access high sensitivity troponin (hsTn) I assay have focused on single platforms and laboratories. The purpose of this study was to determineassay robustness across different platform models at multiple sites, platform-specific characteristics, and equivalence to other hsTn methods to be used in a large laboratory network. Barricor plasma was used to assess imprecision, linearity, sensitivity (limit of blank and detection, LOB/LOD), and comparability to the conventional AccuTnI+3 and other hsTn assays. Studies were conducted in at least 3 laboratories using multiple DxI800 and Access2 platforms. Within-laboratory precision was <10% across all target patient pool concentrations, however, DxI800 mean values were 20% higher than Access2 in the range of 3.6 to 44.9 ng/L. LOBs and LODs were lower on the DxI800, 0.27 and 0.90 ng/L, respectively, compared to 2.9 and 3.2 ng/L on Access2. Both showed excellent linearity across the full range. In method comparison to AccuTnI+3, DxI800 showed a higher slope (0.9417 versus 0.8495) and positive bias (18.1% versus -9.9%) compared to Access2, a trend further increased at concentrations <150 ng/L. At values <150ng/L, there was good agreement with Abbott hsTnI (slope=1.017, r=0.932), but poor agreement with the Roche hsTnT assay (slope=1.687, r=0.589). Inter-laboratory split sample comparisons across 2 DxI800 and 9 Access2 sites showed equivalency between them, except at low concentrations <10ng/L where DxI800 was 2.8 ng/L higher (p<0.001). The Beckman hsTnI assay showed robust analytical performance across different laboratories/platforms. Excellent precision and sensitivity make it suitable for accelerated AMI protocols. However, discrepancies in assay performance between platforms can lead to major errors when using rapid rule-out algorithm.